Brands
Django Snaps Up Snabbit’s Digital Gig
Creative agency to turbocharge hyperlocal home-services brand’s growth.
MUMBAI: Django has just grabbed the quickest mandate in town and it’s all about getting chores done in a flash. India’s next-gen creative and digital agency Django has landed the digital and creative account for Snabbit, the hyperlocal quick-service platform that’s making domestic help feel more like food delivery than a day-long wait. Launched in 2024, Snabbit promises vetted, in-house professionals at your doorstep within 10–15 minutes for cleaning, laundry, kitchen help and other everyday household tasks. The app-driven, full-stack model aims to tidy up the notoriously fragmented and unorganised domestic-help sector with reliability and speed.
Under the new partnership, Django takes the reins on Snabbit’s entire digital playbook from overall strategy and social-media firepower to sharp storytelling that builds trust and cuts through the noise in the booming convenience-services space.
The tie-up comes as Snabbit pushes to widen its footprint across major Indian cities, chasing the growing tribe of time-starved urban households who want chores handled without the drama.
Both sides see the collaboration as more than a standard agency-client deal; it’s a joint mission to craft a crisp, modern narrative that positions Snabbit as the default, dependable answer to daily home hassles delivered fast, fuss-free and with zero second-guessing.
With Django’s creative edge now backing Snabbit’s rapid scaling ambitions, expect the brand’s digital presence to get noticeably snappier in the months ahead. In a market where convenience is the new currency, being able to summon help faster than you can say “laundry day” could prove a winning formula.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
